Financial Data and Key Metrics Changes - Q3 revenue was $283 million, slightly better than forecast but down 2.4% from $290.3 million in the prior year, primarily due to lower eye and ear care category sales [5][12] - Adjusted EPS was $1.14, down from $1.22 in the prior year, reflecting lower sales and increased costs [7][12] - Free cash flow was $209 million year to date, up 13% versus the prior year, allowing for stock repurchases and acquisitions [7][18] Business Line Data and Key Metrics Changes - Sales declines were largely due to Clear Eyes supply constraints, impacting the eye care category [12][14] - Strong growth was observed in e-commerce channels, offsetting declines in other categories like analgesics and cough and colds [15][21] - The women's health segment showed volatility, with Monistat performing well while Summer's Eve faced challenges [39] Market Data and Key Metrics Changes - North America segment revenues decreased 4.4%, while international segment revenues decreased 90 basis points [14] - E-commerce consumption grew over 10% in Q3, indicating a shift in consumer purchasing behavior [35] Company Strategy and Development Direction - The company is focused on improving Clear Eyes supply through strategic actions, including acquiring Pillar5 and adding new suppliers [9][10] - A disciplined capital allocation strategy is in place, prioritizing investments in brands, M&A, and share repurchases [19][20] - The company anticipates a revenue forecast of approximately $1.1 billion for fiscal 2026, reflecting consumption momentum in growth channels [21] Management's Comments on Operating Environment and Future Outlook - Management noted heightened business environment uncertainty due to supply chain constraints, high inflation, and geopolitical events [4] - Confidence remains in the core business, with expectations for free cash flow growth for the fiscal year [8][21] - Sequential improvement in Clear Eyes supply is anticipated, contributing to a positive outlook for the next fiscal year [21] Other Important Information - The company experienced a $10 million write-off related to a supplier loan, which was secured by the supplier's assets [12][13] - Adjusted gross margin for the first nine months was 55.7%, up 50 basis points from the prior year [16] Q&A Session Summary Question: Are consumers shifting to other retailers? - Management confirmed a continuation of channel shifts, with consumption patterns adapting to where consumers choose to shop [24][25] Question: When might the headwinds subside? - Management indicated that it is difficult to predict, as volatility has been high, but they are well-positioned to manage through it [26] Question: Update on eye care supply and margins? - Management expects sequential improvement in Clear Eyes supply but noted that restocking will take time; margins are expected to remain stable [33][34] Question: E-commerce growth and penetration? - E-commerce consumption grew over 10% in Q3, with management noting the importance of adapting marketing strategies to connect with consumers [35][36] Question: Capital allocation and stock repurchases? - Management emphasized that investing in brands is the top priority, but they are also evaluating M&A opportunities while repurchasing shares at attractive levels [44][45] Question: Sales outlook for the fourth quarter? - Management explained that the sales guidance reflects order patterns observed in Q3, with consumption remaining strong [50][51] Question: Future M&A focus? - Management indicated that future M&A will primarily focus on brands and long-term brand building value [69]

Core Insights - Prestige Consumer Healthcare (PBH) is focused on brand building and portfolio expansion through strategic acquisitions, which is expected to drive growth in upcoming quarters [1][5] - The company has experienced a share price increase of 19.3% over the past year, outperforming the industry and S&P 500 [1] Company Overview - PBH has a market capitalization of $4.17 billion and reported an earnings surprise of 5.17% in the last quarter [2] - The earnings yield for PBH stands at 5.4%, significantly higher than the industry's 0.3% [2] Growth Drivers - The strength of PBH's diversified portfolio, which includes well-recognized consumer brands, has contributed to sales growth and long-term profitability, with core brands generating nearly 58.6% of total revenues in fiscal 2024 [3] - The gastrointestinal (GI) product category is a significant contributor, accounting for nearly 20% of North American sales, with brands like Dramamine, Fleet, and Gaviscon leading the category [4] - The company is also seeing growth in the e-commerce channel, reflecting a long-term trend towards online purchases [4] Strategic Acquisitions - PBH has expanded its brand portfolio through both organic growth and acquisitions, including the purchase of TheraTears and other over-the-counter brands from Akorn Operating Company LLC, as well as Hydralyte from Hydration Pharmaceuticals Trust [5] Financial Concerns - As of the end of the fiscal third quarter, PBH had a long-term debt of $996 million and cash and cash equivalents of $51 million, with a debt-to-capital ratio of 35.8% [7] - The company generated approximately 14.8% of its fiscal 2024 revenues from international business, making it susceptible to currency fluctuations [9] Earnings Estimates - The Zacks Consensus Estimate for PBH's fiscal 2025 earnings per share has increased by 0.4% to $4.52, with revenue estimates at $1.13 billion, reflecting a 0.5% increase from the previous year [10]